EternoGen Aesthetics is led by a group of proven industry veterans with decades of collective leadership experience in medical aesthetics. They have been responsible for the development, launch and exits of a number of the industry leading brands including RESTYLANE. EVOLENCE, RADIESSE, JUVEDERM ULTRA and BOTOX. The company founders are an award-winning group of academic researchers from University of Missouri led by Professor Sheila Grant, a world authority in bioengineering.
For a more detailed profile of each of the management team please click the image to view.
Anna Tenstam CEO and Chairman
The bulk of Anna Tenstam’s experience over the past 25 years has been honed in executive positions in the pharmaceutical, medical device and medical aesthetics worldwide. Anna has served as Chairman and on the Board of Directors for private and public healthcare companies since 2004. She currently holds the seat as Chairman for both Eternogen (US) and Timesulin (UK). Former positions include Chief Commercial Officer at Contura International, Co-founder and CEO of Nordic Aesthetics, Global VP of the aesthetics business unit at Q-Med AB, Executive VP of ColBar LifeScience Ltd - M&A by Johnson & Johnson - various positions within Bristol-Myers Squibb and various managerial positions within Pharmacia Diagnostics. Anna holds degrees in science, executive marketing, economy and psychology. In 2003, she was named ‘One of the most powerful business women in Sweden 2003’ and ‘One of the most powerful business people under 40 years old’. Business Week named Anna one of the 125 important businesswomen in both 2003 and 2004 and she has been a member of said Alumni since 2003. In 1995 Anna received the President’s Award at Bristol Myers Squibb and was a member of the Swedish Society for pharmaceutical development in 1995 and 1996. A keynote speaker at a number of international aesthetics forums over the years, including the American Academy of Dermatology in San Francisco in 2006 and IMCAS Paris in 2009 and 2010, Anna has been a member of the ‘Who's Who’ executive network since 2007. Lately, Anna has been prioritizing her role as mentor to aspiring business people looking to enter the world of medicine. Though it may not seem possible, Anna finds time in her busy schedule to entertain friends at home and recharges her batteries by spending time with her two daughters at home in Stockholm.
Luis R. Jimenez - President and Chief Operations Officer
His experience includes the production validation a molecular-based prostate cancer diagnostic assay with J&J. He later went on to work with Bio-tech Pharmacal, a nutraceutical manufacturing company where he designed and implemented a GMP manufacturing quality system. His experience includes operations, quality control in cGMP manufacturing, regulatory affairs for manufacturing, design engineering, technology transfer and project management. Mr. Jimenez’s background includes Chemical Engineering, Cum Laude and a Masters of Business Administration with Academic Excellence.
Professor Sheila Grant, PhD - Chief Technology Officer
She is a founder of EternoGen and principal inventor of the NanoMatrix Technology. As such she is the expert technological platform manager. She is a professor in the Department of Biological Engineering at the University of Missouri with an emphasis in biomaterials. Dr. Grant is an expert in synthetic and organic tissue engineering at the University of Missouri. Her specific research interests involve developing nanostructured biocomposites. Her work addresses in-vivo analysis of tissue integration into novel biocomposites for soft tissue replacement as well as materials characterisation of explanted biomaterials.
Dale DeVore, PhD - Chief Scientific Officer
He is a leading commercialisation scientific expert in collagen dermal filler products. He has demonstrated his ability to adapt innovative technical challenges and master subject matter. Dale's experience in dermal fillers includes founding Autologen, the 2nd dermal filler approved by the FDA. He was Vice President of R&D for BioForm Medical commercialising Radiesse® and serving in FDA panel meetings. His experience also includes consulting for Sculptra® and for CollPlant, LLD. Dale brings over 35 years in clinical development and R&D. He has authored over 75 patents in dermal filler related innovations including EternoGen’s RPC technology. He has strong expertise and experience of modifying formulations, troubleshooting issues and solving complex biochemical issues.
Charles Weatherstone - Chief Commercial Officer
He is a specialist in medical aesthetic marketing, having been responsible for the development, launch and management of a number of market leading brands including JUVEDERM® ULTRA, BOTOX®, PDS® PLATES and RESTYLANE®. Charles has almost 20 years experience in blue chip and start-up health care marketing covering both medical device and pharmaceutical sectors. Charles combines solid strategic planning, broad industry connections and creative execution to create the perfect marketing storm. He received a BSc Hons in 1991 from Southampton University, UK.
Rebecca Rone, MSE - Director of Clinical and Regulatory Affairs
She received her Masters of Science Degree in Bioengineering from the University of California-San Diego with a research focus in cartilage tissue engineering. While in graduate school, Ms. Rone gained experience at BREG as a design engineer for orthopaedic, reconstructive, and postoperative medical devices. She is a co-inventor of the EternoGen’s technology. She was also Associate Director and later Director of the Coulter Translational Partnership at the University of Missouri directing over $1M in R&D grants to commercialising cutting edge research projects.
Robert Brooks - Director of Quality Assurance & Quality Control
He has more than 25 years of combined research and development experience ranging from academic research to drug development. During this time, he developed and validated bioanalytical and CMC analytical methods for APIs and drug products in various matrices at both large and small pharmaceutical companies. He has worked for CMOs and CROs that specialise in both clinical and chemical research, and much of his experience has been in cGMP and GLP environments. In addition he has over 10 years of experience in laboratory supervision and management, including QC management experience, and method development management.
Dave Grant, MSE - Director of R&D
He is a founder of EternoGen and co-inventor CG NanoMtrix technology and expert material characterisation manager. He has over 12 years of biomaterials research involvement including developing bionanocomposite materials utilising metallic nanoparticles conjugated to acellular tissue or type I collagen. His work is inclusive of several patent applications; he specializes in physiological and biological characterisation of biomaterials.